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 The adenosine system has become a promising target for the treatment of schizophrenia 
due to its unique relationship with dopamine D2 receptors. Dopamine D2 receptors display 
heightened sensitivity in schizophrenia, and inhibition of these receptors has been shown to 
alleviate some of the psychotic symptoms of the disorder. Inhibition of adenosine A(2A) 
receptors has been shown to decrease dopamine D2 receptor sensitivity, making this receptor a 
potential target for treatment of the disorder. This effect occurs because adenosine A(2A) 
receptors form a mutually inhibitory heterodimeric complex with dopamine D2 receptors. The 
present study looked at the effects of an adenosine agonist on prepulse inhibition (PPI) and 
cyclic-AMP response binding element protein (CREB) concentrations in the nucleus accumbens 
(NAc) using a rodent model of schizophrenia (NQ model) that presents with increased D2 
receptor sensitivity. Results showed that the A(2A) agonist was effective in improving PPI in 
NQ-treated animals. The agonist was also effective in reducing increased CREB concentrations 
in the NAc of NQ-treated animals to control levels. The effectiveness of the agonist suggests that 
the adenosine system may be a viable target for the treatment of some of the psychotic symptoms 





According to the National Institute of Mental Health, schizophrenia is a neurological 
disorder affecting approximately 1% of the population and involves both positive and negative 
symptoms, as well as cognitive deficits (NIMH, 2018). Positive symptoms of the disorder can 
include hallucinations and delusions, whereas the negative symptoms involve emotional 
disruptions, including anhedonia, lack of will, and reduced speech. Lastly, cognitive deficits 
associated with the disorder can include impaired working memory, reduced mental speed, and 
reduced reaction times (Lesh et al., 2011). Antipsychotic medications are usually prescribed to 
individuals diagnosed with schizophrenia to alleviate some of the described symptoms, but the 
current medications have been shown to have only moderate efficacy and significant harmful 
side effects (Rummel-Kluge, 2010; Leucht, 2013), with nearly 75% of individuals quitting 
treatment within a year (Gray, 2010).  
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 Inhibition of dopamine D2 receptors to decrease dopamine signaling is the mechanism 
used by current antipsychotics to treat the symptoms of schizophrenia.  Heightened dopamine D2 
receptor sensitivity is an important underlying mechanism in the pathology of schizophrenia 
(McCutcheon et al., 2020). Therefore, inhibition of dopamine D2 receptors has been shown to 
alleviate some of the psychotic symptoms of the disorder. This is the mechanism shared by all 
current antipsychotic medications, but the harmful side effects associated with these medications 
call for a better alternative.  
 The adenosine system has emerged as a possible target for treatment of the disorder, 
specifically the psychotic symptoms (Boison et al., 2012). Adenosine is a neuromodulator that 
regulates the release of dopamine and glutamate. Past research has shown that stimulating the 
adenosine A(2A) receptor (agonist) reduces the sensitivity of dopamine D2 receptors. This effect 
is hypothesized to occur because the adenosine A(2A) receptor forms a heterodimer complex 
with dopamine D2 receptors (Borroto-Escuela and Fuxe, 2017), resulting in a mutually inhibitory 
interaction between the two receptors when the adenosine A(2A) receptor is stimulated (Filip et 
al., 2012; Díaz-Cabiale, 2001). Due to this interaction, an adenosine A(2A) agonist has the 
potential to decrease dopamine D2 receptor sensitivity and potentially alleviate some of the 
psychotic symptoms associated with schizophrenia (Domenici et al., 2019).  
The goal of the present study was to investigate the effectiveness of an adenosine A(2A) 
agonist (CGS 21680) in alleviating auditory sensorimotor gating deficits, a behavioral hallmark 
of schizophrenia, using the neonatal quinpirole rodent model of schizophrenia. Analysis of the 
efficacy of the agonist is crucial in determining whether an adenosine A(2A) agonist can be 
therapeutic and potentially provide an alternative to the current antipsychotic medications in use. 
The neonatal quinpirole model was a model developed in Dr.  Richard Kostrzewa’s laboratory 
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(Kostrzewa, 2012). Increased dopamine D2 receptor sensitivity is increased through neonatal 
treatment with quinpirole, a dopamine D2-like agonist, and is independent of a change in receptor 
number. Increased dopamine D2 receptor sensitivity has been shown to play a major role in 
schizophrenia symptomology (Abi-Dargham et al., 2000). This model has been validated through 
a number of studies and is consistent with many aspects of schizophrenia pathology (Brown et 
al., 2012 and 2018; Peterson et al., 2017).  
Important to this study, NQ treatments have been shown to produce auditory 
sensorimotor gating deficits using prepulse inhibition (Thacker et al., 2006; Maple et al., 2015). 
Auditory sensorimotor gating is the regulation of the transmission of auditory information to the 
motor system, and prepulse inhibition (PPI) of startle is a measure of sensorimotor gating in 
which a weak (decibel; dB) auditory stimulus is delivered 250 milliseconds (ms) before a strong, 
intense startling stimulus. The presentation of the weak stimulus 250 milliseconds (ms) before 
the startling stimulus predicts the startle response, and the animal learns to inhibit the startle 
response. The mechanism underlying prepulse inhibition (PPI) is the “gating” or filtering of the 
auditory information received before transmission to the motor system. PPI is a good quantitative 
measure of behavioral and neurological deficits associated with schizophrenia, as well as the 
effects of therapeutic drug treatments in the NQ model because deficits in auditory sensorimotor 
gating are related to dopamine D2 receptor activation, as well as positive and negative symptoms 
directly associated with schizophrenia and cognitive deficits (Braff et al., 1995; Swerdlow et al., 
2006).  
The underlying neural circuitry of auditory sensorimotor gating has been mapped and 
involves a number of prominent forebrain structures, including, and key to this study, the nucleus 
accumbens (Brown et al., 2018; Kumari and Sharma, 2002). For this reason, cyclic-AMP 
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response element-binding protein (CREB) levels in the nucleus accumbens were analyzed. 
CREB is a neurobiological protein downstream of glial cell-line derived neurotrophic factor 
(GDNF) and brain-derived neurotrophic factor (BDNF). Both GDNF and BDNF are 
neurotrophic factors shown to be important in neural plasticity, as well as the behavioral 
responses in the NQ model, and are important in neural and behavioral functioning in individuals 
diagnosed with schizophrenia (Peterson et al., 2017; Brown et al., 2018).  Reports have shown 
that CREB is an important regulator of both BDNF and GDNF and has also been linked directly 
to behavioral deficits observed in schizophrenia (Wang et al., 2018). Importantly, research has 
shown that chronic quinpirole treatment to adult rats results increased CREB levels in the 
nucleus accumbens (Culm et al., 2004), which is associated with behavioral deficits associated 
with emotional regulation.  
The overall hypothesis is that the adenosine agonist CGS 21680 will be successful in 
alleviating sensorimotor gating deficits in the neonatal quinpirole rat model. This will be 
achieved through the agonist decreasing the sensitivity of the dopamine D2 receptor through the 
A(2A)/D2 heteromer. It is also hypothesized that neonatal treatment with quinpirole by itself will 
result in significant sensorimotor gating deficits, along with significant increases of levels of 
CREB in the nucleus accumbens. Lastly, it is hypothesized that treatment with the adenosine 
agonist will reduce CREB levels in the rats neonatally treated with quinpirole to control levels. 
 
Methods 
Subjects: A total of 71 Sprague-Dawley rats were used as subjects in this experiment. Both male 
and female rats were used as subjects, and one subject per litter was assigned per treatment 
condition to control for within litter variance. The animals were housed socially in groups of two 
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or three in climate-controlled housing under a 12-hour light/dark cycle, with food available ad 
libitum. The housing conditions and procedures were compliant with regulations of both East 
Tennessee State University Animal Care and Use Committee and the National Institutes of 
Health Guide for the Care and Use of Animals. 
 
Neonatal Drug Treatment: The day of birth was counted as postnatal day (P)0. The day after 
birth, subjects were administered a single intraperitoneal (IP) injection daily of either 0.9% saline 
(NS) or 1 mg/kg quinpirole (NQ). This treatment continued from P1-21. Subjects were weighed 
daily, and the treatment dose administered was 1% of their body weight. From P21-44 there were 
no drug treatments administered, and the subjects were moved to social housing (2-4 per cage).  
 
PPI Methods: On P44, behavioral testing began. All animals were tested in a behavioral 
apparatus specialized for PPI behavioral analysis (Kinder Scientific, Inc., Poway, CA). Different 
groups of NS or NQ-treated rats were IP administered one of three treatments: saline, saline + 
0.09 mg/kg CGS 21680, or saline + 0.03 mg/kg CGS 21680. 15 minutes after the injection, the 
subjects were tested for three consecutive days using PPI. For PPI testing, rats were randomly 
assigned and administered three different trial types. The trial types included pulse trials, 
prepulse trials, and no stimulus trials. A pulse trial is a 120 dB startle pulse administered alone.  
A prepulse trial is an auditory stimulus that is 3, 6, or 12 dB above the 70 dB background noise 
(73, 76, and 82 dB).  A no stimulus trial is a trial in which no stimulus is given.  
The testing apparatus was a stainless-steel dome attached to a platform mounted on a 
stainless-steel ellipse in a sound-attenuating chamber. On each daily session, the subjects were 
placed into the dome and given a 5-minute habituation period with only the background noise 
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(70 dB white noise) presented. All animals underwent 25 randomized trials which included 5 
pulse, 5 no stimulus, and 15 prepulse trials (5 trials of each 73, 76, and 82dB). The subject’s 
behavioral response was recorded during a 250 ms window immediately after the stimulus was 
presented and was measured in Newtons (N).  
 
CREB Analysis: On P50, approximately 24 h after the locomotor activity test, brain tissue was 
harvested and the NAc was dissected away and placed into a pre-weighed 1.5 ml Eppendorf 
vial. Tissue was homogenized using a Fisher Scientific (Atlanta, GA) Dismembrator 5000.  
Tissue was in a RIPA buffer that contained protease and phosphatase inhibitors to protect the 
sample (P0044, P5726, P8340 and phenylmethylsulfonyl fluoride). Tissue was centrifuged twice 
at 4oC. CREB was analyzed using an ELISA kit from MyBioSource.com (San Diego, CA, USA; 
Cat. No. MBS2098054), and the protocol was closely followed. In brief, the standard provided 
was serially diluted from 20ng/ml to 0.312 ng/ml and run in duplicate. Homogenized samples 
were also run in duplicate across the entire 96-well plate. After the standards and samples were 
applied to the plate, the plate was incubated for 1 hour at 37oC. Liquid was removed from each 
well, and 100µl of detection reagent A was applied—diluted 100-fold with the provided diluent 
in the kit. After another 1-hour incubation at 37oC, the plate was washed three times, and 100µl 
of detection reagent B was applied, also diluted 100-fold with the diluent provided. After a 30 
min incubation at 37oC, the plate was washed five times using the wash buffer provided in the 
kit. Ninety microliters of the substrate solution, which was 3’3’5’5’ tetramethylbenzadine 
(TMB), was applied to the plate. After a 20-min incubation at 37oC, the stop solution was 
applied and the plate was read immediately at 450 nm on a BioTek Plate Reader elx800 (BioTek, 
Winooski, VT). The data provided was calculated according to the standard curve and converted 
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to picograms of CREB/mg weight of the tissue.  
 
Results 
 PPI behavioral test: The data obtained from PPI testing was analyzed using ANOVA, 
and the Newman-Keuls post hoc test was used to analyze any significant interactions. Percent of 
PPI is shown as a function of the decibel of the prepulse administered in Figure 1. A four-way 
ANOVA did not reveal any significant main effects or interactions involving sex as a variable. 
Thus, this factor was dropped and a three-way ANOVA with neonatal drug treatment, adolescent 
drug treatment and decibel level as factors revealed significant main effects of decibel level 
F(2,130)=578.12, p<.001 and  neonatal drug treatment F(1,65)=5.29, p<.024, significant two-
way interactions of neonatal drug treatment x adolescent drug treatment F(2,65)=7.55, p<.001) 
and adolescent drug treatment x decibel level F(4,130)=6.28, p<.001, as well as a significant 
three-way interaction of neonatal drug treatment x adolescent drug treatment x decibel level 
F(4,130)=3.44, p<.01 As seen in Figure 1, the Q-S treatment group (neonatal quinpirole, 
adolescent saline) showed significant deficits in 73 dB and 76 dB trials. These deficits confirmed 
that the NQ model was effective in modeling the sensorimotor gating deficits that are a hallmark 
of schizophrenia and are consistent with previous work (Thacker et al., 2006; Maple et al., 2015). 
The Q-0.03 CGS and Q-0.09 CGS groups’ prepulse inhibition levels were elevated to control 
levels at both 73 and 76 dB. In addition, S-0.03 CGS and S-0.09 CGS groups’ PPI levels were 
also equal to control levels (Group S-S). This indicates that both doses of the CGS 21680 worked 
to significantly improve PPI to control levels at 73 dB and 76 dB trials in NQ animals and did 
not result in PPI deficits in controls administered the drug.  
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Figure 1. Percent prepulse inhibition is shown as a function of decibel of the prepulse administered. The 
colored key indicates the different treatment groups. All significant interactions are shown in the graph. * 
indicates a significant interaction (p< 0.05).  
 
CREB Analysis: The data obtained from the CREB analysis was analyzed using ANOVA, and 
the Newman-Keuls post hoc test was used to analyze any significant interactions. The 
concentration of CREB in picograms per milligram tissue (pg/mg) is shown as a function of the 
treatment group. A two-way ANOVA with neonatal and adolescent drug treatment as factors 
revealed significant main effects of neonatal drug treatment F(1,61)=6.71, p<.01, adolescent 
drug treatment F(2,61)=8.44, p<.001, and a significant two-way interaction of neonatal drug 
treatment x adolescent drug treatment F(2,66)=5.35, p<.007. As seen in Figure 2, the 
Quinpirole-Saline (Q-S) treatment group demonstrated significantly elevated accumbal CREB 
protein levels. Q-0.03 CGS and Q-0.09 CGS groups’ accumbal CREB concentrations were 
decreased to control levels, and neither dose of CGS 21680 affected CREB in the NAc. These 
results indicate that both doses of the adenosine agonist were successful in returning accumbal 
CREB concentrations to control levels.  
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Figure 2. CREB concentration in picograms per milligram (pg/mg) is shown as a function of adolescent 
and neonatal drug treatment. The colored key indicates the different treatment groups. All significant 
interactions are shown in the graph. * indicates a significant interaction (p< 0.05). 
 
Discussion 
 Results of this study demonstrated that the NQ model is effective in modeling the 
sensorimotor gating deficits found in schizophrenia (Grillon et al., 1992). In addition, NQ 
treatment increased CREB protein in the nucleus accumbens, which is consistent with past work 
that has shown that stimulation of the dopamine D2 receptor results in an increase in accumbal 
CREB. This may be related to emotional symptoms that are demonstrated during the negative 
symptoms of schizophrenia (Culm et al., 2004; Kring and Moran, 2008). The study also 
demonstrated that both doses of the adenosine A(2A) agonist CGS 21680 (0.03 and 0.09 mg/kg) 
were effective in alleviating sensorimotor gating deficits in the NQ model to control levels.  
Importantly, both doses had no significant effects in controls, which demonstrates that the action 
of this agonist was effective to alleviate PPI deficits in NQ treated rats, but not result in deficits 
in controls. There were no deficits in NQ treated rats on the 82dB trials, suggesting that 
sensorimotor gating deficits are most prevalent on prepulse trials that are more difficult to 
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associate, because these lower dB trials are closer in level to the white noise baseline. Finally, 
the agonist lowered CREB levels in the NAc of NQ treated rats to control levels. Overall, the 
results confirmed our original hypothesis that CGS 21680 would be effective in improving PPI in 
the NQ model as well as alleviating increases in accumbal CREB.  
 Prepulse inhibition deficits are a hallmark of schizophrenia, as well as numerous other 
brain disorders (Swerdlow et al., 2016) and have been suggested as a biomarker for the disorder 
(Walters and Owen, 2007). PPI deficits associated with the disorder have been hypothesized to 
be related to impaired cognitive function known to be present in schizophrenia. PPI is a 
reflection of the ability to regulate the amount and relevancy of sensory information being 
processed at a particular time, and, since PPI is impaired in SZ, it is thought that these deficits 
may be the cause of the sensory information overload associated with the disorder (Cadenhead et 
al., 1997). PPI is a measure of the ability to filter relevant sensory information, and 
measurements of PPI have shown that sensorimotor gating is impaired in patients diagnosed with 
schizophrenia (Braff et al., 1992). Sensorimotor gating impairment in rodent models is attributed 
to increased dopamine in the NAc (Braff and Geyer, 1990). This may be a reason why 
antipsychotics that inhibit the dopamine D2 receptor in rodents are effective in reducing PPI 
deficits (Geyer et al., 2001). Since adenosine A(2A) agonists also act to indirectly inhibit the 
dopamine D2 receptor, they should also be effective in reducing PPI deficits. This hypothesis was 
supported by our results which showed that both doses of the agonist were effective in reducing 
PPI deficits. The validity of the use of the NQ model in measuring PPI deficits related to SZ has 
been confirmed in several labs (Maple et al., 2015; Wan and Swerdlow, 1993). 
Sex differences in symptomology are present in human schizophrenia (Abel et al., 2010), 
as well as with rodent models of schizophrenia (Hill, 2016). There is conflicting evidence, 
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however, to whether there are sex differences associated with PPI in rodent schizophrenia 
models. Some work has provided evidence of sex differences in PPI in rats (Monte et al., 2017), 
whereas other research has found no sex differences between male and females (Moran et al., 
2016; Gogos et al., 2017). In past work, we did not find sex differences in PPI (Maple et al., 
2015), and likewise, we did not discover sex differences in PPI in the present study.  
 The results from the CREB analysis in the NAc complemented the behavioral data, 
supporting the PPI results. First, results showed that the NQ-saline group demonstrated a robust 
increase in levels of CREB in the nucleus accumbens. Second, these results also supported our 
initial hypothesis that treatment with the agonist would lower CREB to control levels in the CGS 
treatment groups.  
Abnormalities in the expression of CREB in the nucleus accumbens have been found in 
schizophrenia, with research suggesting a link between CREB expression and the 
pathophysiology of the brain’s emotional system in schizophrenia (Wang et al., 2018). A 
reduction of CREB signaling pathways have been shown to assist in the recovery of 
sensorimotor gating deficits (Culm et al., 2004). Abnormalities in CREB expression have also 
been implicated in reduction of emotional reactivity. Elevated CREB levels in the NAc have 
been shown to be correlated with the lack of sensitivity to emotional and stress stimuli in rodents 
(Barrot et al., 2002), consistent with the negative symptomology of schizophrenia. Increases in 
CREB in the NAc have also been shown to be associated with depressive-like effects, drug 
tolerance, and drug dependence (Carlezon et al., 2005).  It is well known that patients suffering 
from schizophrenia demonstrate vulnerability for drug addiction, and epidemiology studies have 
shown dramatic increases of cigarette smoking, cannabis use, and alcoholism in this population 
(Batel, 2000; Reiger et al., 1990). In the current study, the CREB analysis showed that both 
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treatment dosages of CGS 21680 resulted in significantly lowered CREB concentrations in the 
NAc which suggests that an agonist of the adenosine A(2A) receptor may be effective in 
improving emotional reactivity, as well as stimulating recovery of sensorimotor gating deficits.  
Limitations. The generalizability of the results is limited by the sample size and the use 
of a rodent model. With a sample size of 71 and 6 treatment groups, there was a relatively small 
N, with approximately 12 animals (6 males, 6 females) per group. The statistical power, 
however, was still high enough to conduct statistical analyses with confidence. The conclusions 
of this research are also constrained by the use of a rodent model of schizophrenia. A rodent 
model cannot encapsulate all of the aspects of human schizophrenia. For example, we cannot 
model paranoia or other positive symptoms present in schizophrenia. Therefore, it is beyond the 
scope of this study to make any grand conclusions regarding the efficacy of an adenosine agonist 
as a treatment for human schizophrenia, although it is known that adenosine A(2A) agonists are 
currently in clinical trial and, although some have failed, more recent work has shown some 
promising results (Jacobson et al, 2019). The NQ model, however, does encapsulate the neural 
and behavioral hallmarks of schizophrenia relevant to this study, including sensorimotor gating 
impairment, increased CREB in the NAc, and increased dopamine D2 receptor sensitivity (see 
Brown et al, 2012, for review). Modeling of these neural and behavioral hallmarks allows for 
analysis of the underlying mechanisms that cause these abnormalities, as well as possible 
treatments. The results of this study cannot comment on the efficacy of an adenosine agonist for 
the treatment of human schizophrenia, but it can determine the efficacy of an adenosine agonist 
in a rodent schizophrenia model. Success in a rodent model will call for further research in a 
broader scope.  
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 Conclusions. This research was aimed to analyze the effectiveness of the use of an 
adenosine A(2A) receptor agonist to relieve sensorimotor gating impairment in an NQ model of 
schizophrenia. Based on the results of this study, it can be concluded that both doses of CGS 
21680, the adenosine A(2A) agonist, were effective in alleviating PPI deficits in NQ-treated rats. 
Both doses of the agonist were also effective in reducing the increase of CREB protein in the 
NAc produced by NQ treatment.  These results support the possibility that the adenosine A(2A) 
receptor poses as a viable target for the treatment of some of the psychotic symptoms associated 
with schizophrenia. Current antipsychotics used for the treatment of schizophrenia have only 
limited efficacy and many unwanted side effects (Rummel-Kluge, 2010; Leucht, 2013). In 
addition, some antipsychotics have also been shown to further elevate PPI deficits (Geyer et al., 
2001). The adenosine system, however, appears to be an effective treatment in rodent 
schizophrenia models, with limited side effects. The agonist was effective in reducing PPI 
deficits and CREB concentrations in the NAc, both of which are associated with the 
improvement of schizophrenia symptoms. Future work should focus on determining whether 
chronic treatment with an adenosine A(2A) agonist is viable. Studies regarding chronic 
adenosine agonist treatment would be helpful in determining optimal dosage and conditions to 
maximize effectiveness while minimizing side effects. Chemical and pharmacological strategies 
to improve the current delivery and inhibition mechanisms of the adenosine A(2A) agonist 
should also be developed to optimize treatments. Results of this study confirm that the use of an 
adenosine agonist on the adenosine A(2A) receptor is effective in reducing PPI deficits and 
CREB concentrations in the NAc in a rodent schizophrenia model, adding further compelling 
evidence that future research should explore the use of an adenosine agonist as an antipsychotic 
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